(phenyl(CH2)nCOOH." Applicants assume that the Examiner means to refer to compounds in which **R_5 is $-L_3-M_3$** and **M_3 is phenyl$(CH_2)_n$COOH**. Absent a statement to the contrary by the Examiner, Applicants also assume that if the generic claim is found to be allowable, all the claimed subject matter will be allowed, in accordance with the usual practice where there is an election of species under 37 C.F.R. 1.146. Should any of these assumptions be incorrect, Applicants respectfully request clarification.

Claims 1-20 have been rejected under 35 U.S.C. § 112, second paragraph, as being indefinite due to inclusion of the terms "preferably" and "not limited to". Applicants have amended claims 1-9 to delete the improper terminology, and also to make the claims more concise. These amendments are made for the purpose of clarity and do not change the scope of the claims. Applicants respectfully request withdrawal of this rejection in view of the aforementioned amendments.

Claims 1, 5-7, and 20 have been rejected under 35 U.S.C. § 102(b) as being anticipated by Archer (3,189,617). The Examiner has indicated that when R_3 is OH the claimed compound is the enol form of the ketone in reference example D2. Applicants *traverse this rejection for the reasons set forth below.*

The compound of reference example D2 contains a 2-carboxyphenyl moiety bonded to the nitrogen ring atom. The location of this moiety corresponds to R_5 in the claimed compound; however, the claimed definition of R_5 does not include 2-carboxyphenyl. Consequently, the claimed compound where R_3 is OH is not the enol form of the prior art ketone compound. Applicants wish to respectfully point out that R_5 cannot be M_3, but can be $-L_3-M_3$, which means that the L_3 linking group is attached to the ring nitrogen atom. Applicants believe that the claimed compounds are novel, and also are not obvious from knowledge of the prior art. Applicants respectfully request withdrawal of this rejection.

Claims 1-9 and 16-20 are objected to as being directed to "a misjoinder of inventions as recited above." Applicants traverse this objection. Nowhere in the office action is a "misjoinder of invention" mentioned, nor have the Applicants been given any explanation or reasons for such a conclusion. Applicants guess (without knowing) that the Examiner is referring to the election of species requirement, but do not understand what the Examiner deems to be a misjoinder of invention. If the Examiner is attempting to issue a restriction requirement, he should so state and provide reasons for the requirement in accordance with MPEP sections 803, 808, 809 and 816. Applicants would then have an opportunity to

consider the reasons and make a determination whether the restriction should be accepted or traversed.

Applicants respectfully request withdrawal of the aforementioned rejections and objections, allowance of claims 1-20, and prompt advancement of the case to issue. No fee is believed to be due herewith, but should a fee be due it should be charged to Deposit Acct. No. 01-1425.



Joseph M. Mazzarese

Reg. No. **32,803**

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940-0874
Tel. No. (973) 683-2150

Version With Markings To Show Changes Made

--1 (Amended). A compound of the formulae:



or



wherein:

R_1 and $R_{1'}$ are independently selected from H, halogen, $-CF_3$, -OH, $-C_1$-C_{10} alkyl, -S-C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1$-$C_6)$, $-N(C_1$-$C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

or a moiety of the formulae:



R_6 is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-C(O)CH_3$, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

R_7 is selected from $-(CH_2)_n$-COOH, $-(CH_2)_n$-N-(C_1-C_6 alkyl)$_2$, $-(CH_2)_n$-NH-(C_1-C_6 alkyl), $-CF_3$, C_1-C_6 alkyl, C_3-C_5 cycloalkyl, C_1-C_6 alkoxy, -NH-(C_1-C_6 alkyl), -N-(C_1-C_6 alkyl)$_2$, pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, $(CH_2)_n$phenyl, phenyl,-O-phenyl, benzyl, -O-benzyl,

adamantyl, or morpholinyl, -$(CH_2)_n$-phenyl-O-phenyl, -$(CH_2)_n$-phenyl-CH_2-phenyl, -$(CH_2)_n$-O-phenyl-CH_2-phenyl, -$(CH_2)_n$-phenyl-(O-CH_2-phenyl)$_2$,the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, -NH_2, -NO_2, -CF_3,CO_2H, or -OH;

R_2 is selected from H, halogen, -CF_3, -OH, -C_1-C_{10} alkyl, [preferably -C_1-C_6 alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] -CHO, -CN, -NO_2, -NH_2, -NH-C_1-C_6 alkyl, -N(C_1-C_6 alkyl)$_2$, -N-SO_2-C_1-C_6 alkyl, or -SO_2-C_1-C_6 alkyl;

R_3 is selected from H, -CF_3, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, -C_1-C_6 alkyl, -C_3-C_{10} cycloalkyl, -CHO, halogen, $(CH_2)_nC(O)NH_2$ or a moiety of the formula –L^1-M^1:

L^1 indicates a linking or bridging group of the formulae -$(CH_2)_n$-, -S-, -O-, -C(O)-, -$(CH_2)_n$-C(O)-, -$(CH_2)_n$-C(O)-$(CH_2)_n$-, -$(CH_2)_n$-O-$(CH_2)_n$-, or -$(CH_2)_n$-S-$(CH_2)_n$-, C(O)C(O)X, -$(CH_2)_n$-N-$(CH_2)_n$-;

M^1 is selected from:

a) H, the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, [preferably C_1-C_6 alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] -NO_2, -NH_2, -CN, or -CF_3; or

b) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O [including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, isothiazole, isoxazole, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazole, pyrazoline, imidazole, tetrazole, oxathiazole], the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, [preferably C_1-C_6 alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] -NO_2, -NH_2, -CN, or -CF_3; or

c) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O [including, but not limited to, pyran, pyridine, pyrazine, pyrimidine, pyridazine, piperidine, piperazine, tetrazine, thiazine, thiadizine, oxazine, or morpholine], the six-membered heterocyclic ring being optionally substituted by from 1 to 3

substituents selected from halogen, C_1-C_{10} alkyl, [preferably C_1-C_6 alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] -CHO, -NO_2, -NH_2, -CN, -CF_3 or -OH; or

d) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O [including, but not limited to *benzofuran, chromene, indole, isoindole, indoline, isoindoline, napthalene, purine, indolizine,* indazole, quinoline, isoquinoline, quinolizine, quinazoline, cinnoline, phthalazine, or napthyridine], the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents *selected from halogen,* C_1-C_{10} *alkyl, [preferably* C_1-C_6 alkyl,] C_1-C_{10} *alkoxy, [preferably* C_1-C_6 alkoxy,] -CHO, -NO_2, -NH_2, -CN, -CF_3 or -OH;

R_4 is selected from the group of C_1-C_8 lower alkyl, C_1-C_8 lower alkoxy, -$(CH_2)_n$-C_3-C_6 cycloalkyl, -$(CH_2)_n$-S-$(CH_2)_n$-C_3-C_5 cycloalkyl, -$(CH_2)_n$-O-$(CH_2)_n$-C_3-C_5 cycloalkyl, or the groups of:

a) -$(CH_2)_n$-phenyl-O-phenyl, -$(CH_2)_n$-phenyl-CH_2-phenyl, -$(CH_2)_n$-O-phenyl-CH_2-phenyl, -$(CH_2)_n$-phenyl-(O-CH_2-phenyl)$_2$, or a moiety of the formulae:





wherein n is independently selected in each appearance as an integer from 0 to 3, [preferably 0 to 2, more preferably 0 to 1,] Y is C_3-C_5 cycloalkyl, phenyl, benzyl, napthyl, pyridinyl, quinolyl, furyl, thienyl or pyrrolyl; rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, -NH_2, -NO_2 or a five membered heterocyclic ring containing one heteroatom selected from N, S, *or O[, preferably S or O]; or*

b) a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or -CF_3;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, [preferably 1 to 2,] substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or -NO_2; or

c) a moiety of the formulae:



,



,



,



,



, or



;

wherein Z is O or S and the phenyl and pyrimidinyl rings of each moiety are optionally and independently substituted by from 1 to 3 substituents selected from halogen, $-CF_3$, -OH, $-C_1$-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, or $-NO_2$; or

d) a moiety of the formula $-L^2-M^2$, wherein:

L^2 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, -S-, -O-, $-SO_2-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, -C(O)C(O)X;
where X = O,N

M^2 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, [preferably C_1-C_6 alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

i) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O [including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, pyrrolidine, or tetrazole], the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, [preferably C_1-C_6 alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

ii) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O [including, but not limited to pyridine, pyrimidine, *piperidine, piperazine, or morpholine*], *the six-membered heterocyclic ring being optionally* substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, [preferably C_1-C_6 alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH; or

iii) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O [including, but not limited to benzofuran, indole, indoline, napthalene, purine, or quinoline], the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, [preferably C_1-C_6 alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH;

n is an integer from 0 to 3;

R_5 is selected from -COOH, -C(O)-COOH, -$(CH_2)_n$-C(O)-COOH, -$(CH_2)_n$-COOH, $(CH_2)_n$-CH=CH-COOH, -$(CH_2)_n$-tetrazole, -CH_2-phenyl-C(O)-benzothiazole, or



,


,



,



or


;

or a moiety selected from the formulae –L^3-M^3;

wherein L^3 is a bridging or linking moiety selected from a chemical bond, -$(CH_2)_n$-, -S-, -O-, -SO_2-, -C(O)-, -$(CH_2)_n$-C(O)-, -$(CH_2)_n$-C(O)-$(CH_2)_n$-, -$(CH_2)_n$-O-$(CH_2)_n$-,-$(CH_2)_n$-S-$(CH_2)_n$-, -C(Z)-N(R_6)-, -C(Z)-N(R_6)-$(CH_2)_n$-, -C(O)-C(Z)-N(R_6)-, -C(O)-C(Z)-N(R_6)-$(CH_2)_n$-, -C(Z)-NH-SO_2-, -C(Z)-NH-SO_2-$(CH_2)_n$-, -$(CH_2)_n$-S-$(CH_2)_n$-, -$(CH_2)_n$-SO-$(CH_2)_n$-, -$(CH_2)_n$-SO_2-$(CH_2)_n$-, or –$(CH_2)_n$-CH=CH-$(CH_2)_n$-O-;

M^3 is selected from the group of -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole,



,[,]


,







where R_8, R_9 or R_{10} can be attached anywhere in the cyclic or bicyclic system,
n is an integer from 0 to 3;

R_8, in each appearance, is independently selected from H, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, tetrazole, -C(O)-NH_2, $-(CH_2)_n$-C(O)-NH_2,



n is an integer from 0 to 3;

R_9 is selected from H, halogen, $-CF_3$, -OH, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, $-C_1$-C_6 alkyl, -O-C_1-C_6 alkyl, -NH(C_1-C_6 alkyl), or -N(C_1-C_6 alkyl)$_2$;
n is an integer from 0 to 3;

R_{10} is selected from the group of H, halogen, $-CF_3$, -OH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, $-C_1$-C_6 alkyl, -O-C_1-C_6 alkyl, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$,





or 
or 






, or 
;

R_{11} is selected from H, C_1-C_6 lower alkyl, C_1-C_6 cycloalkyl, -CF_3, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH,


;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5, R_8, R_9, R_{10}, and/or R_{11} shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: -C(O)-NH_2, -$(CH_2)_n$-C(O)-NH_2,



n is an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.

2 (Amended). A compound of Claim 1 [of the formula:]



wherein:

R_1 and $R_{1'}$ are independently selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, $-S-C_1-C_{10}$ alkyl, C_1-C_{10} alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, or -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

[R_2 is selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, preferably $-C_1-C_6$ alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, -CN, $-NO_2$, $-NH_2$, $-NH-C_1-C_6$ alkyl, $-N(C_1-C_6$ alkyl$)_2$, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

R_3 is selected from H, $-CF_3$, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, $-C_1-C_6$ alkyl, $-C_3-C_{10}$ cycloalkyl, -CHO, halogen, or $(CH_2)_nC(O)NH_2$ or a moiety of the formula $-L^1-M^1$:

L^1 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, -S-, -O-, -C(O)-, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, C(O)C(O)X, $-(CH_2)_n-N-(CH_2)_n-$,]

M^1 is selected from: H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, [preferably C_1-C_6 alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] $-NO_2$, $-NH_2$, -CN, or $-CF_3$;

R_4 is a moiety of the formulae $-(CH_2)_n$-A, $-(CH_2)_n$-S-A, or $-(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3 substituents selected from H, halogen, $-CF_3$, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or $-NO_2$;
or a pharmaceutically acceptable salt thereof.

3 (Amended). A compound of Claim 2 wherein R_4 is the moiety:



B and C are phenyl optionally substituted by from 1 to 3 substituents selected from H, halogen, $-CF_3$, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or $-NO_2$; and R_1, $R_{1'}$, R_2, R_3, R_5, L^1, M^1 and D are as defined in Claim 2; or a pharmaceutically acceptable salt thereof.

4 (Amended). A compound of Claim 1 [having the formulae:]



wherein:

[R_1 and $R_{1'}$ are independently selected from H, halogen, $-CF_3$, -OH, $-C_1$-C_{10} alkyl, *preferably* $-C_1$-C_6 *alkyl*, $-S-C_1$-C_{10} *alkyl*, *preferably* $-S-C_1$-C_6 *alkyl*, C_1-C_{10} *alkoxy*, *preferably* C_1-C_6 alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1$-$C_6)$, $-N(C_1$-$C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

or R_1 and $R_{1'}$ are independently a moiety of the formulae:



R_6 is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-C(O)CH_3$, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

R_7 is selected from $-(CH_2)_n$-COOH, $-(CH_2)_n-N-(C_1$-C_6 alkyl$)_2$, $-(CH_2)_n-NH-(C_1$-C_6 alkyl), $-CF_3$, C_1-C_6 alkyl, C_3-C_5 cycloalkyl, C_1-C_6 alkoxy, $-NH-(C_1$-C_6 alkyl), $-N-(C_1$-C_6 alkyl$)_2$, *pyridinyl, thienyl, furyl, pyrrolyl, quinolyl,* $(CH_2)_n$*phenyl, phenyl,-O-phenyl, benzyl,* -O-*benzyl,* adamantyl, or morpholinyl, $-(CH_2)_n$-phenyl-O-phenyl, $-(CH_2)_n$-phenyl-CH_2-phenyl, $-(CH_2)_n$-O-

phenyl-CH_2-phenyl, -$(CH_2)_n$-phenyl-(O-CH_2-phenyl)$_2$,the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, -NH_2, -NO_2, -CF_3,CO_2H, or -OH;

R_2 is selected from H, halogen, -CF_3, -OH, -C_1-C_{10} alkyl, preferably -C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, -CN, -NO_2, -NH_2, -NH-C_1-C_6 alkyl, -N(C_1-C_6 alkyl)$_2$, -N-SO_2-C_1-C_6 alkyl, or -SO_2-C_1-C_6 alkyl;

R_3 is selected from H, -CF_3, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, -C_1-C_6 alkyl, -C_3-C_{10} cycloalkyl, -CHO, halogen, $(CH_2)_nC(O)NH_2$ or a moiety of the formula –L^1-M^1:

L^1 indicates a linking or bridging group of the formulae -$(CH_2)_n$-, -S-, -O-, -C(O)-, -$(CH_2)_n$-C(O)-, -$(CH_2)_n$-C(O)-$(CH_2)_n$-, -$(CH_2)_n$-O-$(CH_2)_n$-, or -$(CH_2)_n$-S-$(CH_2)_n$-, C(O)C(O)X, -$(CH_2)_n$-N-$(CH_2)_n$

M^1 is selected from:

a) H, the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -NO_2, -NH_2, -CN, or -CF_3; or

b) *a five-membered heterocyclic ring containing one or two ring heteroatoms* selected from N, S or O including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, isothiazole, isoxazole, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazole, pyrazoline, imidazole, tetrazole, oxathiazole, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -NO_2, -NH_2, -CN, or -CF_3; or

c) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O including, but not limited to, pyran, pyridine, pyrazine, pyrimidine, pyridazine, piperidine, piperazine, tetrazine, thiazine, thiadizine, oxazine, or morpholine, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, -NO_2, -NH_2, -CN, -CF_3 or -OH; or

d) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to benzofuran, chromene, indole, isoindole, indoline, isoindoline, napthalene, purine, indolizine, indazole, quinoline, isoquinoline, quinolizine, quinazoline, cinnoline, phthalazine, or napthyridine, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH;]

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, $-(CH_2)_n$-C_3-C_6 cycloalkyl, $-(CH_2)_n$-S-$(CH_2)_n$-C_3-C_5 cycloalkyl, $-(CH_2)_n$-O-$(CH_2)_n$-C_3-C_5 cycloalkyl, or the groups of:

a) a moiety of the formulae $-(CH_2)_n$-A, $-(CH_2)_n$-S-A, or $-(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, [preferably 1 to 2,] substituents selected from H, halogen, $-CF_3$, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or $-NO_2$; or

b) a moiety of the formula $-L^2$-M^2, wherein L^2 and M^2 are as defined in claim 1; [:

L^2 indicates a linking or bridging group of the formulae $-(CH_2)_n$-, -S-, -O-, $-SO_2$-, -C(O)-, $-(CH_2)_n$-C(O)-, $-(CH_2)_n$-C(O)-$(CH_2)_n$-, $-(CH_2)_n$-O-$(CH_2)_n$-, or $-(CH_2)_n$-S-$(CH_2)_n$-, -C(O)C(O)X;
where X = O,N

M^2 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

i) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, pyrrolidine, or tetrazole, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

ii) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O including, but not limited to pyridine, pyrimidine, piperidine, piperazine, or morpholine, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH; or

iii) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to *benzofuran, indole, indoline, napthalene, purine, or quinoline, the bicyclic ring moiety being* optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH;

n is an integer from 0 to 3;]

R_5 is selected from -COOH, -C(O)-COOH, $-(CH_2)_n$-C(O)-COOH, $-(CH_2)_n$-COOH, $(CH_2)_n$-CH=CH-COOH, $-(CH_2)_n$-tetrazole, $-CH_2$-phenyl-C(O)-benzothiazole, or



;

or a moiety selected from the formulae $-L^3$-M^3 wherein L^3 and M^3 are as defined in claim 1;

[wherein L^3 is a bridging or linking moiety selected from a chemical bond, -$(CH_2)_n$-, -S-, -O-, -SO_2-, -C(O)-, -$(CH_2)_n$-C(O)-, -$(CH_2)_n$-C(O)-$(CH_2)_n$-, -$(CH_2)_n$-O-$(CH_2)_n$-,-$(CH_2)_n$-S-$(CH_2)_n$-, -C(Z)-N(R_6)-, -C(Z)-N(R_6)-$(CH_2)_n$-, -C(O)-C(Z)-N(R_6)-, -C(O)-C(Z)-N(R_6)-$(CH_2)_n$-, -C(Z)-NH-SO_2-, -C(Z)-NH-SO_2-$(CH_2)_n$-, -$(CH_2)_n$-S-$(CH_2)_n$-, -$(CH_2)_n$-SO-$(CH_2)_n$-, -$(CH_2)_n$-SO_2-$(CH_2)_n$-, or –$(CH_2)_n$-CH=CH-$(CH_2)_n$-O-;

M^3 *is selected from the group of* -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole,













where R_8, R_9 or R_{10} can be attached anywhere in the cyclic or bicyclic system,
n is an integer from 0 to 3;

R_8, in each appearance, is independently selected from H, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole, -C(O)-NH_2, -$(CH_2)_n$-C(O)-NH_2,


, or  ;

n is an integer from 0 to 3;

R_9 is selected from H, halogen, $-CF_3$, -OH, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, $-C_1$-C_6 alkyl, $-O-C_1$-C_6 alkyl, $-NH(C_1$-C_6 alkyl), or $-N(C_1$-C_6 alkyl$)_2$;

n is an integer from 0 to 3;

R_{10} is selected from the group of H, halogen, $-CF_3$, -OH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, $-C_1$-C_6 alkyl, $-O-C_1$-C_6 alkyl, $-NH(C_1$-C_6 alkyl), $-N(C_1$-C_6 alkyl$)_2$,


,

,

,


,

,

or 
(C1-C6 lower alkyl),
or 
(C1-C6 lower haloalkyl),


(C1-C6 lower alkyl),

,


,

,



n is an integer from 0 to 3;

R_{11} is selected from H, C_1-C_6 lower alkyl, C_1-C_6 cycloalkyl, $-CF_3$, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH,



with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5, R_8, R_9, R_{10}, and/or R_{11} shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-C(O)-NH_2$, $-(CH_2)_n-C(O)-NH_2$,



n is an integer from 0 to 3;]

or a pharmaceutically acceptable salt thereof.

5 (Amended). A compound of Claim 1 [having the formulae:]



wherein:

R_1 is H;

[R_1 is selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, preferably $-C_1-C_6$ alkyl, $-S-C_1-C_{10}$ alkyl, preferably $-S-C_1-C_6$ alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

or R_1 and $R_{1'}$ are independently a moiety of the formulae:



R_6 is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-C(O)CH_3$, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

R_7 is selected from $-(CH_2)_n-COOH$, $-(CH_2)_n-N-(C_1-C_6$ alkyl$)_2$, $-(CH_2)_n-NH-(C_1-C_6$ alkyl), $-CF_3$, C_1-C_6 alkyl, C_3-C_5 cycloalkyl, C_1-C_6 alkoxy, $-NH-(C_1-C_6$ alkyl), $-N-(C_1-C_6$ alkyl$)_2$, pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, $(CH_2)_n$phenyl, phenyl,-O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl, $-(CH_2)_n$-phenyl-O-phenyl, $-(CH_2)_n$-phenyl-CH_2-phenyl, $-(CH_2)_n$-O-phenyl-CH_2-phenyl, $-(CH_2)_n$-phenyl-(O-CH_2-phenyl$)_2$,the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$, $-CF_3$,CO_2H, or -OH;

R_2 is selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, preferably $-C_1-C_6$ alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, -CN, $-NO_2$, $-NH_2$, $-NH-C_1-C_6$ alkyl, $-N(C_1-C_6$ alkyl$)_2$, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

R_3 is selected from H, $-CF_3$, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, -C_1-C_6 alkyl, -C_3-C_{10} cycloalkyl, -CHO, halogen, $-(CH_2)_nC(O)NH_2$ or a moiety of the formula $-L^1-M^1$:

L^1 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, -S-, -O-, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, $C(O)C(O)X$, or $-(CH_2)_n-N-(CH_2)_n$;
where X is O or N

M^1 is selected from:

a) H, the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

b) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, isothiazole, isoxazole, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazole, pyrazoline, imidazole, tetrazole, oxathiazole, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

c) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O including, but not limited to, pyran, pyridine, pyrazine, pyrimidine, pyridazine, piperidine, piperazine, tetrazine, thiazine, thiadizine, oxazine, or morpholine, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH; or

d) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to benzofuran, chromene, indole, isoindole, indoline, isoindoline, napthalene, purine, indolizine, indazole, quinoline, isoquinoline, quinolizine, quinazoline, cinnoline, phthalazine, or napthyridine, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents

selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, -NO_2, -NH_2, -CN, -CF_3 or -OH;]

R_4 is selected from the group of C_1-C_8 lower alkyl, C_1-C_6 lower alkoxy, -$(CH_2)_n$-C_3-C_6 cycloalkyl, -$(CH_2)_n$-S-$(CH_2)_n$-C_3-C_5 cycloalkyl, -$(CH_2)_n$-O-$(CH_2)_n$-C_3-C_5 cycloalkyl, or [the *groups of:*

a)]a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or -CF_3;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, [preferably 1 to 2,] substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or -NO_2;

R_5 is selected from -COOH, -C(O)-COOH, -$(CH_2)_n$-C(O)-COOH, -$(CH_2)_n$-COOH, $(CH_2)_n$-CH=CH-COOH, -$(CH_2)_n$-tetrazole, or



;

or a moiety selected from the formulae –L^3-M^3;

wherein L^3 is a bridging or linking moiety selected from a chemical bond, -$(CH_2)_n$-, -SO_2-, -C(O)-, -$(CH_2)_n$-C(O)-, -$(CH_2)_n$-C(O)-$(CH_2)_n$-, -$(CH_2)_n$-O-$(CH_2)_n$-,-$(CH_2)_n$-S-$(CH_2)_n$-, -$(CH_2)_n$-SO-$(CH_2)_n$-, -$(CH_2)_n$-SO_2-$(CH_2)_n$-, or –$(CH_2)_n$-CH=CH-$(CH_2)_n$-O-;

M^3 is selected from the group of -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole,



where R_8, R_9 can be attached anywhere in the cyclic or bicyclic system,
n is an integer from 0 to 3;

R_8, in each appearance, is independently selected from H, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole, -C(O)-NH_2, -$(CH_2)_n$-C(O)-NH_2,



n is an integer from 0 to 3;

R_9 is selected from H, halogen, -CF_3, -OH, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, -C_1-C_6 alkyl, -O-C_1-C_6 alkyl, -NH(C_1-C_6 alkyl), or -N(C_1-C_6 alkyl)$_2$;
n is an integer from 0 to 3;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5, R_8, R_9, shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: -C(O)-NH_2, -$(CH_2)_n$-C(O)-NH_2,



n is an integer from 0 to 3;
or a pharmaceutically acceptable salt thereof.

6 (Amended). A compound of Claim 1 [having the formulae:]



wherein:

R_1 is selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, [preferably $-C_1-C_6$ alkyl,] -S-C_1-C_{10} alkyl, [preferably -S-C_1-C_6 alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] -CN, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

or R_1 and $R_{1'}$ are independently a moiety of the formulae:

or a moiety of the formulae:



R_6 and R_7 are as defined in claim 1;[is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, -$C(O)CH_3$, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

R_7 is selected from $-(CH_2)_n$-COOH, $-(CH_2)_n$-N-(C_1-C_6 alkyl)$_2$, $-(CH_2)_n$-NH-(C_1-C_6 alkyl), $-CF_3$, C_1-C_6 alkyl, C_3-C_5 cycloalkyl, C_1-C_6 alkoxy, -NH-(C_1-C_6 alkyl), -N-(C_1-C_6 alkyl)$_2$, pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, $(CH_2)_n$phenyl, phenyl,-O-phenyl, benzyl, -O-benzyl,

adamantyl, or morpholinyl, -$(CH_2)_n$-phenyl-O-phenyl, -$(CH_2)_n$-phenyl-CH_2-phenyl, -$(CH_2)_n$-O-phenyl-CH_2-phenyl, -$(CH_2)_n$-phenyl-(O-CH_2-phenyl)$_2$,the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, -NH_2, -NO_2, -CF_3,CO_2H, or -OH;

R_2 is selected from H, halogen, -CF_3, -OH, -C_1-C_{10} alkyl, preferably -C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, -CN, -NO_2, -NH_2, -NH-C_1-C_6 alkyl, -N(C_1-C_6 alkyl)$_2$, -N-SO_2-C_1-C_6 alkyl, or -SO_2-C_1-C_6 alkyl;]

R_3 is selected from H, -CF_3, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, -C_1-C_6 alkyl, -C_3-C_{10} cycloalkyl, -CHO, halogen, $(CH_2)_nC(O)NH_2$ or a moiety of the formula –L^1-M^1:

L^1 indicates a linking or bridging group of the formulae -$(CH_2)_n$-, -C(O)-, -$(CH_2)_n$-C(O)-, -$(CH_2)_n$-C(O)-$(CH_2)_n$-, -$(CH_2)_n$-O-$(CH_2)_n$-, or -$(CH_2)_n$-S-$(CH_2)_n$-, C(O)C(O)X, -$(CH_2)_n$-N-$(CH_2)_n$;

M^1 *is selected from*[:

a)] H, the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, [preferably C_1-C_6 alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] -NO_2, -NH_2, -CN, or -CF_3; [or]

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, -$(CH_2)_n$-C_3-C_6 cycloalkyl, -$(CH_2)_n$-S-$(CH_2)_n$-C_3-C_5 cycloalkyl, -$(CH_2)_n$-O-$(CH_2)_n$-C_3-C_5 cycloalkyl, or [the groups of:

a)] *a moiety of the formulae* -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, *or* -$(CH_2)_n$-O-A, *wherein* A *is* the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or -CF_3;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, [preferably 1 to 2,] substituents selected from H, halogen, $-CF_3$, -OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$;

R_5 is selected from -COOH, $-C(O)-COOH$, $-(CH_2)_n-C(O)-COOH$, $-(CH_2)_n-COOH$, $(CH_2)_n-CH=CH-COOH$, $-(CH_2)_n$-*tetrazole, or a moiety selected from the formulae* $-L^3-M^3$;
wherein L^3 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$,$-(CH_2)_n-S-(CH_2)_n-$, $-(CH_2)_n-SO-(CH_2)_n-$, $-(CH_2)_n-SO_2-(CH_2)_n-$, or $-(CH_2)_n-CH=CH-(CH_2)_n-O-$;

M^3 is selected from the group of -COOH, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$, tetrazole,



where R_8, R_9 can be attached anywhere in the cyclic or bicyclic system,
n is an integer from 0 to 3;

R_8, in each appearance, is independently selected from H, -COOH, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$, tetrazole, $-C(O)-NH_2$, $-(CH_2)_n-C(O)-NH_2$,



n is an integer from 0 to 3;

R_9 *is selected from* H, *halogen*, $-CF_3$, -OH, -COOH, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$, $-C_1-C_6$ alkyl, $-O-C_1-C_6$ alkyl, $-NH(C_1-C_6$ alkyl), or $-N(C_1-C_6$ alkyl$)_2$;

n is an integer from 0 to 3;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5, R_8, R_9, shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-C(O)-NH_2$, $-(CH_2)_n-C(O)-NH_2$,



n is an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.

7 (Amended). A compound of Claim 1 [having the formulae:]



wherein:

[R_1 and $R_{1'}$ are independently selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, preferably $-C_1-C_6$ alkyl, $-S-C_1-C_{10}$ alkyl, preferably $-S-C_1-C_6$ alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

or R_1 and $R_{1'}$ are independently a moiety of the formulae:





R_6 is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;]

R_7 is selected from -OH, $-CF_3$, C_1-C_6 alkyl, C_1-C_6 alkoxy, -NH-(C_1-C_6 alkyl), -N-(C_1-C_6 alkyl)$_2$, pyridinyl, thienyl, furyl, pyrrolyl, phenyl, -O-phenyl, benzyl, -O-benzyl, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, -CN, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CF_3$, or -OH;

[R_2 is selected from H, halogen, $-CF_3$, -OH, -C_1-C_{10} alkyl, preferably -C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, -CN, $-NO_2$, $-NH_2$, -NH-C_1-C_6 alkyl, -N(C_1-C_6 alkyl)$_2$, -N-SO_2-C_1-C_6 alkyl, or -SO_2-C_1-C_6 alkyl;]

R_3 is selected from H, -C_1-C_{10} alkyl, [preferably -C_1-C_6 alkyl,] -(CH_2)-OH, $(CH_2)_nC(O)NH_2$, -CH_2-O-(C_1-C_6 alkyl, -CH_2-O-CH_2-phenyl, -CH_2-N-(C_1-C_6 alkyl), -CH_2-N-CH_2-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, $-CF_3$ or -C_1-C_6 alkyl;

X is O or N

n = 0 or 1;

R_4 is a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, [preferably 1 to 2,] substituents selected from H, halogen, $-CF_3$, -OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$;

R_5 is a moiety selected from the groups of:



wherein L^1 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n-$, $-(CH_2)_{n'}-C(O)-(CH_2)_{n'}-$, $-(CH_2)_{n'}-O-(CH_2)_{n'}-$,$-(CH_2)_{n'}-S-(CH_2)_{n'}-$, $-(CH_2)_{n'}-SO-(CH_2)_{n'}-$, $-(CH_2)_{n'}-SO_2-(CH_2)_{n'}-$, or $-(CH_2)_{n'}-CH=CH-(CH_2)_{n'}-O-$;

where n' is an integer from 0 to 5;

R_9 is selected from $-CF_3$, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, $-NH(C_1-C_6$ alkyl), or $-N(C_1-C_6$ alkyl)$_2$,

n in each instance is independently selected as an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.

8 (Amended). A compound of Claim 1 having the formulae:





or



wherein:

R_1 is selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, [preferably $-C_1-C_6$ alkyl,] -S-C_1-C_{10} alkyl, [preferably -S-C_1-C_6 alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] -CN, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

R_2 is selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, [preferably $-C_1-C_6$ alkyl,] C_1-C_{10} alkoxy, [preferably C_1-C_6 alkoxy,] -CHO, -CN, $-NO_2$, $-NH_2$, $-NH-C_1-C_6$ alkyl, $-N(C_1-C_6$ alkyl$)_2$, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

R_3 is selected from H, $-C_1-C_{10}$ alkyl, [preferably $-C_1-C_6$ alkyl,] $-(CH_2)$-OH, $(CH_2)_nC(O)NH_2$, $-CH_2-O-(C_1-C_6$ alkyl), $-CH_2-O-CH_2$-phenyl, $-CH_2-N-(C_1-C_6$ alkyl), $-CH_2-N-CH_2$-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, $-CF_3$ or $-C_1-C_6$ alkyl;

n = 0 or 1.

R_4 is a moiety of the formulae $-(CH_2)_n$-A, $-(CH_2)_n$-S-A, or $-(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, [preferably 1 to 2,] substituents selected from H, halogen, $-CF_3$, -OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$;

R_5 is a moiety selected from the groups of:



wherein L^1 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$,$-(CH_2)_n-S-(CH_2)_n-$, $-(CH_2)_n-SO-(CH_2)_n-$, $-(CH_2)_n-SO_2-(CH_2)_n-$, or $-(CH_2)_n-CH=CH-(CH_2)_n-O-$;
where n = 0-5

R_9 is selected from $-CF_3$, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, $-NH(C_1-C_6$ alkyl), or $-N(C_1-C_6$ alkyl$)_2$,

n in each instance is independently selected as an integer from 0 to 3,
or a pharmaceutically acceptable salt thereof.

9 (Amended). A compound of Claim 1 having the formulae:



or



wherein:

R_1 is selected from H, halogen, $-CF_3$, -OH, -CN, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

R_2 is selected from H, halogen, $-CF_3$, -OH, , -CN, $-NO_2$, $-NH_2$, $-NH-C_1-C_6$ alkyl, $-N(C_1-C_6$ alkyl$)_2$, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

R_3 is selected from H, $-C_1-C_{10}$ alkyl, [preferably $-C_1-C_6$ alkyl,] $-(CH_2)-OH$, $(CH_2)_nC(O)NH_2$, $-CH_2-O-(C_1-C_6$ alkyl), $-CH_2-O-CH_2$-phenyl, $-CH_2-N-(C_1-C_6$ alkyl), $-CH_2-N-CH_2$-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, $-CF_3$ or $-C_1-C_6$ alkyl;

n = 0 or 1.

R_5 is a moiety selected from the groups of:



or



wherein L^1 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_{n'}-$, $-(CH_2)_{n'}-C(O)-(CH_2)_{n'}-$, $-(CH_2)_{n'}-O-(CH_2)_{n'}-$,$-(CH_2)_{n'}-S-(CH_2)_{n'}-$, $-(CH_2)_{n'}-SO-(CH_2)_{n'}-$, $-(CH_2)_{n'}-SO_2-(CH_2)_{n'}-$, or $-(CH_2)_{n'}-CH=CH-(CH_2)_{n'}-O-$;

n' in each instance is independently selected as an integer from 0 to 5;

or a pharmaceutically acceptable salt thereof.--